Endocyte (ECYT) +110.5% premarket after Merck (MRK) agrees to pay the biotech company $120M...


Endocyte (ECYT) +110.5% premarket after Merck (MRK) agrees to pay the biotech company $120M upfront plus milestone payouts of up to $880M to develop and market experimental cancer drug vintafolide, which is being evaluated in a Phase 3 clinical trial for ovarian cancer and a Phase 2 trial for non-small cell lung cancer. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs